Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EIF2AK2 | P19525 | 1/20 | 0.37 |
| ▸ | MAPK1 | P28482 | 4/20 | 0.36 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.36 |
| ▸ | CDK2 | P24941 | 1/20 | 0.36 |
| ▸ | MAPK3 | P27361 | 1/20 | 0.36 |
| ▸ | MKNK1 | Q9BUB5 | 4/20 | 0.35 |
| ▸ | GSK3B | P49841 | 4/20 | 0.35 |
| ▸ | SYK | P43405 | 3/20 | 0.35 |
| ▸ | HDAC8 | Q9BY41 | 2/20 | 0.34 |
| ▸ | MKNK2 | Q9HBH9 | 1/20 | 0.34 |
| ▸ | ROCK2 | O75116 | 2/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2678012 | 0.83 | EIF2AK2 (0.42) | EIF2AK2MAPK1CCNA2CDK2MAPK3 | |
| SCHEMBL6128576 | 0.81 | EIF2AK2 (0.37) | EIF2AK2MAPK1CCNA2CDK2MAPK3 | |
| SCHEMBL2177558 | 0.81 | ACHE (0.51) | HDAC8 | |
| SCHEMBL2180119 | 0.81 | MAPK10 (0.40) | EIF2AK2MAPK1CCNA2CDK2MAPK3 | |
| SCHEMBL2179774 | 0.79 | CLK4 (0.50) | MKNK1 | |
| SCHEMBL2176860 | 0.78 | HDAC3 (0.38) | EIF2AK2MKNK1GSK3BMKNK2 | |
| SCHEMBL2178733 | 0.78 | MKNK1 (0.48) | MKNK1SYK | |
| SCHEMBL2179483 | 0.77 | LMNA (0.39) | MAPK1 | |
| SCHEMBL2179041 | 0.77 | MKNK1 (0.42) | MAPK1MKNK1GSK3BSYKMKNK2 | |
| SCHEMBL2176497 | 0.77 | NCF1 (0.45) | EIF2AK2CCNA2CDK2MKNK1MKNK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110166137-A1 | Substituted Naphthalenyl-Pyrimidine Compounds | ARQULE, INC. (US) | 2011-07-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110166137-A1 | Substituted Naphthalenyl-Pyrimidine Compounds | DPYD, TP53, TYMP | EIF2AK2 1269/4885MAPK1 3178/4885CCNA2 66/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.